Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Benitec Biopharma (NASDAQ: BNTC) will provide a clinical update on BB-301, its gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD).
The company said it will report results for the six patients treated in Cohort 1 of the Phase 1b/2a study and host an investor webcast on November 3, 2025 at 8:00 am EST.
Webcast registration was posted by the company for investor access to the update.
Benitec Biopharma (NASDAQ: BNTC) fornirà un aggiornamento clinico su BB-301, il suo candidato di terapia genica per la distrofia muscolare oculofaringea (OPMD).
L'azienda ha dichiarato che riporterà i risultati di sei pazienti trattati nel Cohort 1 dello studio di Fase 1b/2a e organizzerà un webcast per investitori il 3 novembre 2025 alle ore 8:00 EST.
La registrazione al webcast è stata pubblicata dall'azienda per l'accesso degli investitori all'aggiornamento.
Benitec Biopharma (NASDAQ: BNTC) proporcionará una actualización clínica sobre BB-301, su candidato de terapia génica para la Distrofia Muscular Oculofaríngea (OPMD).
La compañía dijo que informará los resultados de los seis pacientes tratados en la Cohort 1 del estudio de Fase 1b/2a y organizará un webcast para inversores el 3 de noviembre de 2025 a las 8:00 a. m. EST.
La registración del webcast fue publicada por la empresa para el acceso de los inversores a la actualización.
벤이트크 바이오파마(BENITEK Biopharma)는 BB-301, 안구인두 근육위축(OPMD)을 위한 유전자 치료 후보물질에 대한 임상 업데이트를 제공할 예정입니다.
회사는 1b/2a 단계 연구의 코호트 1에서 치료받은 여섯 명의 환자에 대한 결과를 보고하고, 2025년 11월 3일 동부 표준시 8:00에 투자자 대상 웹캐스트를 주최한다고 밝혔습니다.
투자자 접근을 위한 업데이트를 위한 웹캐스트 등록이 회사에 의해 게시되었습니다.
Benitec Biopharma (NASDAQ : BNTC) fera une mise à jour clinique sur BB-301, son candidat de thérapie génique pour la dystrophie musculaire oculo-pharyngée (DMOP).
L'entreprise a indiqué qu'elle communiquera les résultats des six patients traités dans la cohorte 1 de l'étude de phase 1b/2a et organisera un webcast pour les investisseurs le 3 novembre 2025 à 8h00 EST.
L'enregistrement du webcast a été publié par l'entreprise pour l'accès des investisseurs à la mise à jour.
Benitec Biopharma (NASDAQ: BNTC) wird ein klinisches Update zu BB-301, seinem Gentherapie-Kandidaten für die Oculopharyngeale Muskeldystrophie (OPMD), geben.
Das Unternehmen sagte, es werde Ergebnisse der sechs Patienten berichten, die in der Kohorte 1 der Phase-1b/2a-Studie behandelt wurden, und am 3. November 2025 um 8:00 Uhr EST einen Investoren-Webcast ausrichten.
Die Registrierung für den Webcast wurde vom Unternehmen veröffentlicht, damit Investoren Zugriff auf das Update haben.
Benitec Biopharma (ناسداك: BNTC) ستقدّم تحديثاً سريرياً حول BB-301، مرشحها للعلاج الجيني لداء الضمور العضلي العيني البلعومي (OPMD).
وقالت الشركة إنها ستبلّغ عن نتائج المرضى الستة الذين عولجوا في الكوهورت 1 من دراسة المرحلة 1b/2a وستعقد بثاً للمستثمرين في 3 نوفمبر 2025، الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة.
تم نشر تسجيل البث المباشر من قبل الشركة للوصول الاستثماري إلى التحديث.
- None.
- None.
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST
HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that it will provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301 being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
Webcast details:
Date: November 3, 2025
Time: 8:00 am EST
To register for the webcast, please click here.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
What will Benitec (BNTC) update investors about on November 3, 2025?
When and how can investors watch the Benitec (BNTC) BB-301 webcast?
Which study phase is Benitec discussing for BB-301 in OPMD?
How many patients will Benitec report on in the BB-301 Cohort 1 update?
Will the November 3, 2025 Benitec webcast include clinical data for BB-301?
